|
注册号: Registration number: |
ChiCTR2500112235 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-11 17:15:59 |
|
注册时间: Date of Registration: |
2025-11-11 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
含益生菌BBMN68常温酸奶对常年性过敏性鼻炎缓解作用研究 |
|
Public title: |
Effect of Shelf-Stable Yogurt Containing Probiotic BBMN68 on Alleviating Perennial Allergic Rhinitis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
含益生菌BBMN68常温酸奶对常年性过敏性鼻炎缓解作用研究 |
|
Scientific title: |
Effect of Shelf-Stable Yogurt Containing Probiotic BBMN68 on Alleviating Perennial Allergic Rhinitis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
何晶晶 |
研究负责人: |
何晶晶 |
|
Applicant: |
Jingjing He |
Study leader: |
Jingjing He |
|
申请注册联系人电话: Applicant telephone: |
+86 151 2009 2404 |
研究负责人电话:
Study leader's |
+86 151 2009 2404 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hejingjing_89@163.com |
研究负责人电子邮件: Study leader's E-mail: |
hejingjing_89@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区天秀路10号 |
研究负责人通讯地址: |
北京市海淀区天秀路10号 |
|
Applicant address: |
10 Tianxiu Road, Haidian District, Beiiing |
Study leader's address: |
10 Tianxiu Road, Haidian District, Beiiing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国农业大学 |
||
|
Applicant's institution: |
China Agricultural University |
||
|
研究负责人所在单位: |
中国农业大学 |
||
|
Affiliation of the Leader: |
China Agricultural University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
CAUHR-20240803 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国农业大学人体研究伦理委员会 |
||
|
Name of the ethic committee: |
Human Research Ethics Committee of China Agricultural University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-08-15 00:00:00 | ||
|
伦理委员会联系人: |
车会莲 |
||
|
Contact Name of the ethic committee: |
Huilian Che |
||
|
伦理委员会联系地址: |
北京海淀区圆明园西路2号 |
||
|
Contact Address of the ethic committee: |
2 Yuanmingyuan Road West, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 134 3911 5115 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国农业大学 |
||||||||||||||||||||||
|
Primary sponsor: |
China Agricultural University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区天秀路10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
10 Tianxiu Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国农业大学 |
||||||||||||||||||||||
|
Source(s) of funding: |
China Agricultural University |
||||||||||||||||||||||
|
研究疾病: |
过敏性鼻炎 |
||||||||||||||||||||||
|
Target disease: |
Allergic rhinitis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)研究巴氏灭菌酸奶中热灭活长双歧杆菌BBMN68对过敏性鼻炎的缓解作用。 (2)探究酸奶发酵中长双歧杆菌BBMN68添加的适宜剂量。 (3)探索热灭活长双歧杆菌BBMN68缓解过敏性鼻炎的作用机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To investigate the efficacy of heat-inactivated Bifidobacterium longum BBMN68 in pasteurized yogurt in alleviating symptoms of allergic rhinitis. (2) To determine the optimal dosage of Bifidobacterium longum BBMN68 used in yogurt fermentation. (3) To explore the underlying mechanism by which heat-inactivated Bifidobacterium longum BBMN68 alleviates allergic rhinitis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
(1) 诊断出患有除变应性鼻炎外其他变应性疾病(如:皮炎、哮喘)的患者; (2) 合并有上呼吸道感染或鼻窦炎或鼻腔内有息肉的患者; (3) 目前处于怀孕期、哺乳期或备孕期者; (4) 患有先天性免疫疾病; (5) 经常饮用乳酸菌乳制品以及牛奶过敏和乳糖不耐受的患者; (6) 在研究开始前1周内使用过抗组胺药或鼻喷糖皮质激素,或者在研究前3个月使用过口服糖皮质激素的患者; (7) 曾接受过免疫治疗的患者,或定期服用抗炎药的患者; (8) 3个月内接种过疫苗; (9) 其他临床医生认为不适合参加本试验者,以及参与其他临床试验的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Diagnosis of an allergic disease other than allergic rhinitis (e.g., atopic dermatitis, asthma). (2) Presence of comorbid upper respiratory tract infection, sinusitis, or nasal polyps. (3) Currently pregnant, lactating, or planning a pregnancy. (4) History of congenital immunodeficiency. (5) Regular consumption of probiotic supplements or lactobacillus-containing dairy products and known milk allergy or lactose intolerance. (6) Use of antihistamines or intranasal corticosteroids within one week prior to enrollment; or use of oral corticosteroids within three months prior to enrollment. (7) A history of allergen immunotherapy or regular use of anti-inflammatory drugs. (8) Having received any vaccination within the three months prior to enrollment. (9) Concurrent participation in another clinical trial and deemed by the investigator to be unsuitable for the trial for any other reason. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-11-17 00:00:00至 To 2026-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-11-17 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
选用最小随机化法,进行动态随机,使三组间的基线特征尽量均衡。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Minimum randomisation was chosen to perform dynamic randomisation so that the baseline characteristics were as balanced as possible between the three groups. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
随机化分组由独立的统计学家完成。试验中对研究者和受试者设盲,使研究者和受试者均不了解分组。安慰剂与各试验组样品在外观、形状及规格等方面均一致。 |
|
Blinding: |
Randomization was conducted by independent statisticians. The trial was blinded to both the investigators and the subjects, meaning neither party was aware of the treatment group assignments. The placebo was identical to the active treatment groups in terms of appearance, shape, and formulation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
发表文章后,通过邮件与研究者联系申请获得原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the article is published, contact the researchers by email to request the data. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |